• 1
    Engellau J, Bendahl PO, Persson A, et al. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol. 2005; 36: 994-1002.
  • 2
    International Agency for Research on Cancer. WHO Classification of Soft Tissue Tumours. Available at: Accessed August 26, 2012
  • 3
    Ballo MT, Zagars GK. Radiation therapy for soft tissue sarcoma. Surg Oncol Clin North Am. 2003; 12: 449-467, vii.
  • 4
    Bacci G, Lari S. Current treatment of high grade osteosarcoma of the extremity: review. J Chemother. 2001; 13: 235-243.
  • 5
    Phan A, Patel S. Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol. 2003; 4: 433-439.
  • 6
    Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nuclear Med. 2003; 28: 815-820.
  • 7
    Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996; 14: 1679-1689.
  • 8
    Eilber FC, Rosen G, Nelson SD, et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg. 2003; 237: 218-226.
  • 9
    Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004; 54: 94-109.
  • 10
    Ceyssens S, Stroobants S. Sarcoma. Methods Mol Biol. 2011; 727: 191-203.
  • 11
    Eary JF, Conrad EU. Imaging in sarcoma. J Nuclear Med. 2011; 52: 1903-1913.
  • 12
    Volker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007; 25: 5435-5441.
  • 13
    Aisen AM, Martel W, Braunstein EM, McMillin KI, Phillips WA, Kling TF. MRI and CT evaluation of primary bone and soft-tissue tumors. AJR Am J Roentgenol. 1986; 146: 749-756.
  • 14
    Hicks RJ. Functional imaging techniques for evaluation of sarcomas. Cancer Imaging. 2005; 5: 58-65.
  • 15
    Petasnick JP, Turner DA, Charters JR, Gitelis S, Zacharias CE. Soft-tissue masses of the locomotor system: comparison of MR imaging with CT. Radiology. 1986; 160: 125-133.
  • 16
    van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol. 1998; 27: 57-71.
  • 17
    Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nuclear Med. 2003; 44: 1200-1209.
  • 18
    Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nuclear Med. 2000; 41: 1369-1379.
  • 19
    Franzius C, Daldrup-Link HE, Sciuk J, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol. 2001; 12: 479-486.
  • 20
    Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nuclear Med. 2000; 27: 1305-1311.
  • 21
    Gyorke T, Zajic T, Lange A, et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nuclear Med Commun. 2006; 27: 17-24.
  • 22
    Iagaru A, Chawla S, Menendez L, Conti PS. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nuclear Med Commun. 2006; 27: 795-802.
  • 23
    Kleis M, Daldrup-Link H, Matthay K, et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nuclear Med Mol Imaging. 2009; 36: 23-36.
  • 24
    Lucas JD, O'Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg. 1998; 80: 441-447.
  • 25
    Arush MW, Israel O, Postovsky S, et al. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer. 2007; 49: 901-905.
  • 26
    Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbekyan V, Turcotte RE. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nuclear Med Mol Imaging. 2009; 36: 1944-1951.
  • 27
    Franzius C, Daldrup-Link HE, Wagner-Bohn A, et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol. 2002; 13: 157-160.
  • 28
    Gerth HU, Juergens KU, Dirksen U, Gerss J, Schober O, Franzius C. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nuclear Med. 2007; 48: 1932-1939.
  • 29
    Park JY, Kim EN, Kim DY, et al. Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Gynecol Oncol. 2008; 109: 255-262.
  • 30
    Adler LP, Blair HF, Williams RP, et al. Grading liposarcomas with PET using [18F]FDG. J Comput Assist Tomogr. 1990; 14: 960-962.
  • 31
    Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004; 30: 83-101.
  • 32
    Bredella MA, Caputo GR, Steinbach LS. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol. 2002; 179: 1145-1150.
  • 33
    Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res. 1998; 4: 1215-1220.
  • 34
    Eary JF, O'sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nuclear Med Mol Imaging. 2002; 29: 1149-1154.
  • 35
    Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nuclear Med. 1988; 29: 181-186.
  • 36
    Knapp EL, Kransdorf MJ, Letson GD. Diagnostic imaging update: soft tissue sarcomas. Cancer Control. 2005; 12: 22-26.
  • 37
    McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol. 2005; 184: 1293-1304.
  • 38
    Neville HL, Andrassy RJ, Lobe TE, et al. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J Pediatr Surg. 2000; 35: 317-321.
  • 39
    Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nuclear Med. 1996; 37: 257-261.
  • 40
    Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005; 103: 339-348.
  • 41
    Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nuclear Med. 1999; 40: 1637-1643.
  • 42
    Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, et al. Prognostic significance of preoperative [18-F]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg. 2005; 241: 286-294.
  • 43
    Ben Arush MW, Bar Shalom R, Postovsky S, et al. Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities. J Pediatr Hematol Oncol. 2006; 28: 440-445.